Primary Care Takeaways From VESALIUS-CV: Evolocumab Efficacy -

Name: Primary Care Takeaways From VESALIUS-CV: Evolocumab Efficacy in Patients Without Significant Atherosclerosis
Uploaded: 2026-04-17T04:00:00+00:00
Duration: 4 min 40 s
Description: Emerging data from VESALIUS-CV at ACC 2026 show that evolocumab can reduce cardiovascular events even in patients without significant atherosclerosis. In t

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Bringing PAH Care Home with Wearables and Telemedicine
Bringing PAH Care Home with Wearables and Telemedicine
Clinician's Roundtable
Bringing PAH Care Home with Wearables and Telemedicine
- Daniel Lachant, D.O.
Understanding CPET for Athletes: Protocols and Pitfalls
Understanding CPET for Athletes: Protocols and Pitfalls
Heart Matters
Understanding CPET for Athletes: Protocols and Pitfalls
- Benjamin Levine, MD, FACC
Leveraging Wearables for Pulmonary Arterial Hypertension Care
Leveraging Wearables for Pulmonary Arterial Hypertension Care
Clinician's Roundtable
Leveraging Wearables for Pulmonary Arterial Hypertension Care
- Daniel Lachant, D.O.
Advances in Sports Cardiology: Updates from ACC 2026
Advances in Sports Cardiology: Updates from ACC 2026
Heart Matters
Advances in Sports Cardiology: Updates from ACC 2026
- Jeffrey Hsu, MD, PhD

Primary Care Takeaways From VESALIUS-CV: Evolocumab Efficacy in Patients Without Significant Atherosclerosis

Recommended

Title

Share on ReachMD

Welcome to Global Cardiology Academy

Welcome to Global
Cardiology Academy